WASHINGTON (PNN) - August 5, 2025 - In a move that many were hoping for but were not expecting, HHS Secretary Robert F. Kennedy, Jr. just announced that Biomedical Advanced Research and Development Authority (BARDA) will be canceling 22 mRNA vaccine development contracts, saving taxpayers about $500 million in the process.
This move delivered a major blow to the biomedical industrial complex, which was hoping to make an mRNA vaccine for just about every disease imaginable.
The reason for this move is grounded in what happened during the COVID-19 debacle, which Kennedy explained in detail.
He shared how “mRNA vaccines don’t perform well against viruses that infect the upper respiratory tract. mRNA only codes for a small part of the viral proteins, usually a single antigen. One mutation, and the vaccine becomes ineffective,” said Kennedy.
The next revelation was a big surprise.
Kennedy confirmed that the COVID-19 shots could have caused the mutations and extended the pandemic.
He explained. “The [mRNA] vaccine [platform] paradoxically encourages new mutations and can actually prolong pandemics. As the virus constantly mutates to escape the protective effects of the vaccine, millions of people, maybe even you or someone you know, caught the Omicron variant despite being vaccinated. That is because a single mutation can make mRNA vaccines ineffective.”
Kennedy’s comments echo what vaccinologist Dr. Geert Vanden Bossche has been saying for the better part of four years.
He warned, “You are generating a breeding ground for even more infectious variants to replicate” when you vaccinate during a pandemic.
With the conclusion that mRNA shots are ineffective against respiratory viruses, prolong pandemics, and encourage mutations, Kennedy declared, “mRNA technology poses more risk than benefits for these respiratory viruses.”
As such, Kennedy announced that BARDA will be cancelling 22 mRNA vaccine contracts, saving taxpayers “just under $500 million” in the process.
He clarified that this isn’t a complete indictment of mRNA technology across the board, but when it comes to respiratory diseases, he believes it offers no benefit to humanity.
“That is why we are moving beyond the limitations of mRNA for respiratory viruses and investing in better solutions,” said Kennedy.